Literature DB >> 2265108

Micro-osteoclast resorption as a characteristic feature of B-cell malignancies other than multiple myeloma.

J F Rossi1, D Chappard, C Marcelli, J Laplante, T Commes, P Baldet, C Janbon, J Jourdan, C Alexandre, R Bataille.   

Abstract

Multiple myeloma (MM) is characterized by the presence of lytic bone lesion and frequent hypercalcaemia. These are due to an excessive osteoclastic resorption in association with a low bone formation, as demonstrated by bone histomorphometry. Conversely, B-cell malignancies other than MM are rarely associated with lytic bone lesion and/or hypercalcaemia. In this study we have analysed quantitative bone histology in 65 patients with B-cell malignancies other than MM at diagnosis: chronic lymphocytic leukaemia (CLL, n = 20), non-Hodgkin's lymphoma (NHL, n = 25), Waldenström's disease (WD, n = 14), hairy cell leukaemia (HCL, n = 6). Fifty patients presented no clinical evidence of increased bone resorption, including no lytic bone lesions radiologically detectable and/or no hypercalcaemia. 80% of these patients (40/50) had increased bone resorption parameter using quantitative bone histology, including 19/29 (65.5%) patients with CLL or WD and 21/21 (100%) patients with NHL or HCL (P less than 0.01). As a control group, seven patients lacking bone marrow involvement on bone sample presented no excessive bone resorption. However, eight patients presented lytic bone lesions and/or hypercalcaemia. All of these patients had increased resorption parameters with high numbers of osteoclasts per surface trabecular bone (mean = 35.3), as opposed to the patients lacking lytic bone lesions and/or hypercalcaemia (mean = 6.6, n = 28) and to normal individuals (mean +/- SD = 3.8 +/- 1.7 and 6.3 +/- 2.6, respectively before and after 60 years). In all the cases, excessive histologic bone resorption was mediated by mononuclear small osteoclasts (mean osteoclast length +/- SD = 27.3 +/- 4.1 as compared to normal range = 35.0 +/- 1.0, P less than 0.001). In different in vitro models, these small mononuclear osteoclasts are considered as progenitors. These data suggest an abnormal osteoclast differentiation in B-cell malignancies other than MM, probably due to differences in the production of local factors acting on bone remodelling.

Entities:  

Mesh:

Year:  1990        PMID: 2265108     DOI: 10.1111/j.1365-2141.1990.tb07902.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation.

Authors:  Scott A Ely; Daniel M Knowles
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

2.  Parathyroid hormone related protein (PTHrP) in hypercalcaemia of lymphoproliferative disease.

Authors:  S V Davies; J Vora; C A Wardrop
Journal:  J Clin Pathol       Date:  1993-02       Impact factor: 3.411

3.  Quantification of dendritic cells and osteoclasts in the bone marrow of patients with monoclonal gammopathy.

Authors:  Nicolas Josselin; Hélène Libouban; Mamoun Dib; Norbert Ifrah; Erick Legrand; Michel Félix Baslé; Maurice Audran; Daniel Chappard
Journal:  Pathol Oncol Res       Date:  2008-08-28       Impact factor: 3.201

4.  Factors associated with an increased risk of vertebral fracture in monoclonal gammopathies of undetermined significance.

Authors:  J M Piot; M Royer; A Schmidt-Tanguy; E Hoppé; M Gardembas; T Bourrée; M Hunault; S François; F Boyer; N Ifrah; G Renier; A Chevailler; M Audran; D Chappard; H Libouban; G Mabilleau; E Legrand; B Bouvard
Journal:  Blood Cancer J       Date:  2015-08-28       Impact factor: 11.037

5.  Chronic lymphocytic leukemia cells impair osteoblastogenesis and promote osteoclastogenesis: role of TNFα, IL-6 and IL-11 cytokines.

Authors:  Paolo Giannoni; Cecilia Marini; Giovanna Cutrona; Serena Matis; Maria Cristina Capra; Francesca Puglisi; Paola Luzzi; Simona Pigozzi; Gabriele Gaggero; Antonino Neri; Katia Todoerti; Fortunato Morabito; Adalberto Ibatici; Maurizio Miglino; Micaela Bergamaschi; Silvia Bruno; Gian Mario Sambuceti; Jean Louis Ravetti; Manlio Ferrarini; Franco Fais; Daniela de Totero
Journal:  Haematologica       Date:  2021-10-01       Impact factor: 9.941

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.